Abstracts tagged "antiphospholipid syndrome and classification criteria"

Abstract Number: 145 • 2019 ACR/ARP Annual Meeting
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results
Medha Barbhaiya¹, Stephane Zuily ², Yasaman Ahmadzadeh ³, Raymond Naden ⁴, Karen Costenbader ⁵, Doruk Erkan ⁶ and On Behalf of the New APS Classification Criteria Collaborators ⁷, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Centre Hospitalier Universitaire de Nancy, Nancy, France, ³N/A, Tehran, Iran, ⁴McMaster University, Hamilton, ON, Canada, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Hospital for Special Surgery, New York City, ⁷Hospital for Special Surgery, New York, NY
Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria to identify patients with high likelihood of Antiphospholipid Syndrome…
Abstract Number: 163 • 2018 ACR/ARHP Annual Meeting
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Item Reduction Survey
Medha Barbhaiya¹, Stephane Zuily², Yasaman Ahmadzadeh³, Raymond P. Naden⁴, Karen Costenbader⁵ and Doruk Erkan⁶, ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Université de Lorraine, CHRU Nancy, Nancy, France, ³Hospital for Special Surgery, New York, NY, ⁴New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: An international multidisciplinary effort has been initiated to develop new rigorous, consensus-based criteria to identify patients with high likelihood of having APS. The methodological…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].